Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CHGG -23.1% (also initiating strategic review, files complaint against Google), HIMS -22.1%, NVTS -19.7%, MPLN -17.8%, MRVI -16% (postpones release; reaffirms guidance), TEM -13.3%, UCTT -12.2%, CNNE -11.4%, DNUT -10.2%, MYGN -9.4% (also appoints new CEO), TCOM -8.4%, OFIX -7.3%, CIVI -6.9%, BTDR -6.9%, CECO -6.8%, CRI -6.4%, KTB -6%, AORT -5.2%, CLF -5%, RIOT -4.9%, SHLS -4.9%, IART -4.8%, CLNE -4.1%, LGIH -3.7%, ZM -3.6%, KINS -3.2%, O -3.1%, BLD -3.1%, CWEN -2.9%, SEE -2.9%, DRVN -2.8%, XHR -2.5%, BSM -2.3%, AXGN -2.3%, DDS -2.1%, ZD -1.9%, AESI -1.7% (increases dividend), AS -1.7%, MAX -1.4%, HSIC -1.4%, LTC -1.1%, PLOW -1.1%, BOW -1.1%, GFL -1%, ELAN -1%, DEA -0.9%, PSA -0.8%
Other news:
- BBIO -4.2% (initiates long-term $500 mln debt management strategy)
- TLX -3.5% (receives approval for Illuccix prostate cancer imaging agent in Luxembourg)
- SGHT -2.8% (to present clinical data on OMNI system)
- DRS -2.2% (receives $45 mln U.S. contract)
- CAKE -2% ($450 mln convertible senior notes offering)
- JACK -1.8% (CEO resigning)
- HITI -1.6% (pauses acquisition of Purecan GmbH and explores alternative arrangements with Purecan to enter the german medical cannabis market)
- UL -0.8% (Hein Schumacher is stepping down as Chief Executive Officer)
Analyst comments:
- O -3.1% (downgraded to Neutral from Outperform at Exane BNP Paribas)
- LILA -2.9% (downgraded to Underweight from Equal Weight at Barclays)